RIPK3 and neoplasm: A novel hybrid gene delivery platform combines adeno‐associated virus (AAV)‐mediated receptor‐interacting kinase 3 (RIPK3) expression with manganese dioxide‐polyethyleneimine (MnO2−PEI) nanoshield to induce necroptosis, ferroptosis, and immunogenic cell death, effectively reprogramming the tumor microenvironment.